Prognostic Value of Ki-67 Expression in Advanced Lung Squamous Cell Carcinoma Patients Treated with Chemotherapy

References

• SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• TravisWD. Lung cancer pathology: current concepts. Clin Chest Med. 2020;41(1):67–85. doi:10.1016/j.ccm.2019.11.00132008630
   PubMed Web of Science ®Google Scholar
• ZhangXC, WangJ, ShaoGG, et al. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nat Commun. 2019;10(1):1772. doi:10.1038/s41467-019-09762-130992440
   PubMed Web of Science ®Google Scholar
• ChangYS, TuSJ, ChenYC, et al. Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir Res. 2021;22(1):3. doi:10.1186/s12931-020-01608-533407425
   PubMed Web of Science ®Google Scholar
• Paz-AresL, LuftA, VicenteD, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa181086530280635
   PubMed Web of Science ®Google Scholar
• AngYL, TanHL, SooRA. Best practice in the treatment of advanced squamous cell lung cancer. Ther Adv Respir Dis. 2015;9(5):224–235. doi:10.1177/175346581558114725902866
   PubMed Web of Science ®Google Scholar
• HirschFR, KerrKM, BunnPAJr., et al. Molecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies. Clin Lung Cancer. 2018;19(4):331–339. doi:10.1016/j.cllc.2018.03.01429773328
   PubMed Web of Science ®Google Scholar
• ZhuX, ChenL, HuangB, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225. doi:10.1038/s41598-019-57094-331937819
   PubMed Web of Science ®Google Scholar
• Kammerer-JacquetSF, AhmadA, MøllerH, et al. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Mod Pathol. 2019;32(9):1303–1309. doi:10.1038/s41379-019-0268-y30976102
   PubMed Web of Science ®Google Scholar
• LinL, ChengJ, TangD, et al. The associations among quantitative spectral CT parameters, Ki-67 expression levels and EGFR mutation status in NSCLC. Sci Rep. 2020;10(1):3436. doi:10.1038/s41598-020-60445-032103127
   PubMed Web of Science ®Google Scholar
• XuJ, LiuP, DaJ, HaoJ, PengW, SunG. Prognostic value of Ki-67 in stage I non-small-cell lung cancer: a meta-analysis involving 1931 patients. Pathol Res Pract. 2019;215(5):855–860. doi:10.1016/j.prp.2019.02.02030871912
   PubMed Web of Science ®Google Scholar
• MitchellKG, ParraER, NelsonDB, et al. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(3):911–919.e6. doi:10.1016/j.jtcvs.2019.04.08431235357
   PubMed Web of Science ®Google Scholar
• WenS, ZhouW, LiCM, et al. Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC Cancer. 2015;15:520. doi:10.1186/s12885-015-1524-226174366
   PubMed Web of Science ®Google Scholar
• MartinB, PaesmansM, MascauxC, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91(12):2018–2025. doi:10.1038/sj.bjc.660223315545971
   PubMed Web of Science ®Google Scholar
• MenonSS, GuruvayoorappanC, SakthivelKM, RasmiRR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39–45. doi:10.1016/j.cca.2019.01.01130653951
   PubMed Web of Science ®Google Scholar
• WarthA, CortisJ, SoltermannA, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer. 2014;111(6):1222–1229. doi:10.1038/bjc.2014.40225051406
   PubMed Web of Science ®Google Scholar
• MasudaD, MasudaR, MatsuzakiT, et al. Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma. Mol Med Rep. 2015;12(5):7303–7309. doi:10.3892/mmr.2015.435426459875
   PubMed Web of Science ®Google Scholar
• ZhuWY, HuXF, FangKX, et al. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer. Histol Histopathol. 2019;34(11):1269–1278.31062864
   PubMed Web of Science ®Google Scholar
• PezzutoA, CappuzzoF, D’ArcangeloM, et al. Prognostic value of p16 protein in patients with surgically treated non-small cell lung cancer; relationship with Ki-67 and PD-L1. Anticancer Res. 2020;40(2):983–990. doi:10.21873/anticanres.1403232014943
   PubMed Web of Science ®Google Scholar
• GrantL, BanerjiS, MurphyL, et al. Androgen receptor and Ki67 expression and survival outcomes in non-small cell lung cancer. Horm Cancer. 2018;9(4):288–294. doi:10.1007/s12672-018-0336-729915882
   PubMed Web of Science ®Google Scholar
• JakobsenJN, SørensenJB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79(1):1–7. doi:10.1016/j.lungcan.2012.10.00823137549
   PubMed Web of Science ®Google Scholar
• ThakurMK, GadgeelSM. Predictive and prognostic biomarkers in non-small cell lung cancer. Semin Respir Crit Care Med. 2016;37(5):760–770. doi:10.1055/s-0036-159233727732997
   PubMed Web of Science ®Google Scholar
• ChenRL, ZhouJX, CaoY, et al. The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. Immunotherapy. 2019;11(17):1481–1490. doi:10.2217/imt-2019-010131713453
   PubMed Web of Science ®Google Scholar
• MokTSK, WuYL, KudabaI, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-730955977
   PubMed Web of Science ®Google Scholar
• PawelczykK, PiotrowskaA, CiesielskaU, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(4):824. doi:10.3390/ijms20040824
   PubMed Web of Science ®Google Scholar